Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa

Kim C E Sigaloff, Tina Ramatsebe, Raquel Viana, Tobias F Rinke De Wit, Carole L. Wallis, Wendy S. Stevens

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Patients failing antiretroviral treatment for extended periods of time are at risk of accumulating HIV drug resistance mutations (DRMs), which negatively influences second-line treatment. This retrospective study assessed the rate of DRM accumulation among South African patients with continued virological failure. Serial genotypic resistance testing was performed and DRMs were scored according to the 2009 IAS-USA list. Among 43 patients, 38 (88.4%) harbored ≥1 DRM. The median time between two sequential resistance tests was 5 months (IQR: 3-10). Thymidine analogue mutations accumulated at a rate of 0.07 mutation per month of drug exposure, which is faster than previously reported. Routine virological monitoring should be implemented in resource-limited settings to preserve susceptibility to second-line regimens.

Original languageEnglish
Pages (from-to)171-175
Number of pages5
JournalAIDS Research and Human Retroviruses
Volume28
Issue number2
DOIs
Publication statusPublished - 1 Feb 2012

Cite this

Sigaloff, Kim C E ; Ramatsebe, Tina ; Viana, Raquel ; De Wit, Tobias F Rinke ; Wallis, Carole L. ; Stevens, Wendy S. / Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. In: AIDS Research and Human Retroviruses. 2012 ; Vol. 28, No. 2. pp. 171-175.
@article{3b6bd47aedb8450f968c75b6b4e6d204,
title = "Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa",
abstract = "Patients failing antiretroviral treatment for extended periods of time are at risk of accumulating HIV drug resistance mutations (DRMs), which negatively influences second-line treatment. This retrospective study assessed the rate of DRM accumulation among South African patients with continued virological failure. Serial genotypic resistance testing was performed and DRMs were scored according to the 2009 IAS-USA list. Among 43 patients, 38 (88.4{\%}) harbored ≥1 DRM. The median time between two sequential resistance tests was 5 months (IQR: 3-10). Thymidine analogue mutations accumulated at a rate of 0.07 mutation per month of drug exposure, which is faster than previously reported. Routine virological monitoring should be implemented in resource-limited settings to preserve susceptibility to second-line regimens.",
author = "Sigaloff, {Kim C E} and Tina Ramatsebe and Raquel Viana and {De Wit}, {Tobias F Rinke} and Wallis, {Carole L.} and Stevens, {Wendy S.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1089/aid.2011.0136",
language = "English",
volume = "28",
pages = "171--175",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. / Sigaloff, Kim C E; Ramatsebe, Tina; Viana, Raquel; De Wit, Tobias F Rinke; Wallis, Carole L.; Stevens, Wendy S.

In: AIDS Research and Human Retroviruses, Vol. 28, No. 2, 01.02.2012, p. 171-175.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa

AU - Sigaloff, Kim C E

AU - Ramatsebe, Tina

AU - Viana, Raquel

AU - De Wit, Tobias F Rinke

AU - Wallis, Carole L.

AU - Stevens, Wendy S.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Patients failing antiretroviral treatment for extended periods of time are at risk of accumulating HIV drug resistance mutations (DRMs), which negatively influences second-line treatment. This retrospective study assessed the rate of DRM accumulation among South African patients with continued virological failure. Serial genotypic resistance testing was performed and DRMs were scored according to the 2009 IAS-USA list. Among 43 patients, 38 (88.4%) harbored ≥1 DRM. The median time between two sequential resistance tests was 5 months (IQR: 3-10). Thymidine analogue mutations accumulated at a rate of 0.07 mutation per month of drug exposure, which is faster than previously reported. Routine virological monitoring should be implemented in resource-limited settings to preserve susceptibility to second-line regimens.

AB - Patients failing antiretroviral treatment for extended periods of time are at risk of accumulating HIV drug resistance mutations (DRMs), which negatively influences second-line treatment. This retrospective study assessed the rate of DRM accumulation among South African patients with continued virological failure. Serial genotypic resistance testing was performed and DRMs were scored according to the 2009 IAS-USA list. Among 43 patients, 38 (88.4%) harbored ≥1 DRM. The median time between two sequential resistance tests was 5 months (IQR: 3-10). Thymidine analogue mutations accumulated at a rate of 0.07 mutation per month of drug exposure, which is faster than previously reported. Routine virological monitoring should be implemented in resource-limited settings to preserve susceptibility to second-line regimens.

UR - http://www.scopus.com/inward/record.url?scp=84858043161&partnerID=8YFLogxK

U2 - 10.1089/aid.2011.0136

DO - 10.1089/aid.2011.0136

M3 - Article

VL - 28

SP - 171

EP - 175

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -